Substrate-Driven Mapping of the Degradome by Comparison of Sequence Logos

PLoS Computational Biology

Volumn 9, Issue 11, 2013, Pages

  Fuchs, Julian E ^a   von Grafenstein, Susanne ^a   Huber, Roland G ^a   Kramer, Christian ^a   Liedl, Klaus R ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYMES; INTERFACES (MATERIALS); MOLECULES; PEPTIDES; PRINCIPAL COMPONENT ANALYSIS; TREES (MATHEMATICS);

CLUSTERINGS; COMPARISON OF SEQUENCES; EVOLUTIONARY ORIGIN; PRINCIPAL-COMPONENT ANALYSIS; PROTEOLYTIC ENZYME; SEQUENCE LOGOS; SIMILARITY MATRIX; SMALL MOLECULES; SUBSTRATE RECOGNITION; TREE BRANCHES;

SUBSTRATES;

DEPSIPEPTIDE; DEPSIPEPTIDE GRASSYSTATIN A; NEUROLYSIN; PLASMIN; THIMET OLIGOPEPTIDASE; THROMBIN; TRYPSIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; DATA BASE; DATA MINING; ENZYME DEGRADATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; PEPTIDE MAPPING; PHYLOGENETIC TREE; POSITION WEIGHT MATRIX; PRINCIPAL COMPONENT ANALYSIS; PROTEINASE INHIBITION;

AMINO ACIDS; BINDING SITES; CLUSTER ANALYSIS; DRUG DISCOVERY; PEPTIDE HYDROLASES; PEPTIDES; PRINCIPAL COMPONENT ANALYSIS; PROTEINS; PROTEOMICS;

EID: 84888274187     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003353     Document Type: Article

References (86)

1. Quesada V, Ordonez GR, Sanchez LM, Puente XS, Lopez-Otin C, (2009) The Degradome database: mammalian proteases and diseases of proteolysis. Nucleic Acids Res 37: D239-D243.
2. Puente XS, Sanchez LM, Overall CM, Lopez-Otin C, (2003) Human and Mouse Proteases: A Comparative Genomic Approach. Nat Rev Genet 4: 544-558.
3. Hedstrom L, (2002) Introduction: Proteases. Chem Rev 102: 4429-4429.
4. Fuchs JE, Von Grafenstein S, Huber RG, Margreiter MA, Spitzer GM, et al. (2013) Cleavage Entropy as Quantitative Measure of Protease Specificity. PLOS Comput Biol 9: e1003007.
5. Di Cera E, (2009) Serine Proteases. IUBMB Life 61: 510-515.
6. Lopez-Otin C, Overall CM, (2002) Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol 3: 509-519.
7. Turk B, (2006) Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 5: 785-799.
8. Schechter I, Berger A, (1967) On the Size of the Active Site in Proteases: I. Papain. Biochem Biophys Res Commun 2: 157-162.
9. Madala PK, Tyndall JDA, Nall T, Fairlie DP, (2010) Update 1 of: Proteases Universally Recognize Beta Strands In Their Active Sites. Chem Rev 110: PR1-PR31.
10. Perona JJ, Craik CS, (1995) Structural basis of substrate specificity in the serine proteases. Protein Sci 4: 337-360.
11. Hedstrom L, (2002) Serine Protease Mechanism and Specificity. Chem Rev 102: 4501-4523.
12. Rawlings ND, Barrett AJ, Bateman A, (2012) MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res 40: D343-350 Database accession 8.5.2013.
13. Puente XS, Sanchez LM, Gutierrez-Fernandez A, Velasco G, Lopez-Otin C, (2005) A genomic view of the complexity of mammalian proteolytic systems. Biochem Soc Trans 33: 331-334.
14. Lopez-Otin C, Bond JS, (2008) Proteases: Multifunctional Enzymes in Life and Disease. J Biol Chem 283: 30433-30437.
15. Poreba M, Drag M, (2010) Current strategies for probing substrate specificity of proteases. Curr Med Chem 17: 3968-3995.
16. Schilling O, Overall CM, (2008) Proteome-derived, database-searchable peptide libraries for identifying protease cleavage sites. Nat Biotechnol 6: 685-694.
17. Van Damme P, Staes A, Bronsoms S, Helsens K, Colaert N, et al. (2010) Complementary positional proteomics for screening substrates of endo- and exoproteases. Nat Methods 7: 512-515.
18. O'Donoghue AJ, Eroy-Reveles AA, Knudsen GM, Ingram J, Zhou M, et al. (2012) Global identification of peptidase specificity by multiplex substrate profiling. Nat Methods 9: 1095-1100.
19. Matthews DJ, Wells JA, (1993) Substrate Phage - Selection of Protease Substrates by Monovalent Phage Display. Science 5111: 1113-1117.
20. Boulware KT, Daugherty PS, (2006) Protease specificity determination by using cellular libraries of peptide substrates (CliPS). Proc Nat Acad Sci U S A 20: 7583-7588.
21. Turk BE, Huang LL, Piro ET, Cantlay LC, (2001) Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nat Biotechnol 19: 661-667.
22. Harris JL, Backes BJ, Leonetti F, Mahrus S, Ellman JA, et al. (2000) Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. Proc Natl Acad Sci U S A 14: 7754-7759.
23. Mahrus S, Trinidad JC, Barkan DT, Sali A, Burlingame, et al. (2008) Global Sequencing of Proteolytic Cleavage Sites in Apoptosis by Specific Labeling of Protein N Termini. Cell 134: 866-876.
24. Kleifeld O, Doucet A, Prudova A, Auf dem Keller U, Gioia M, et al. (2011) Identifying and quantifying proteolytic events and the natural N terminome by terminal amine isotopic labeling of substrates. Nat Protocols 6: 1578-1611.
25. Rawlings ND, Barrett AJ, Bateman A, (2010) MEROPS: the peptidase database. Nucleic Acids Res 38: D227-233.
26. Rawlings ND, (2009) A large and accurate collection of peptidase cleavages in the MEROPS database. Database (Oxford) 2009: bap015.
27. Schneider TD, Stephens RM, (1990) Sequence logos: a new way to display consensus sequences. Nucleic Acids Res 20: 6097-6100.
28. Song J, Tan H, Perry AJ, Akutsu T, Webb GI, et al. (2012) PROSPER: An Integrated Feature-Based Tool for Predicting Protease Substrate Cleavage Sites. PLOS One 7: e50300.
29. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, et al. (2011) ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 40: D1100-1107 Database accession 15.5.2013.
30. Igarashi Y, Eroshkin A, Gramatikova S, Gramatikoff K, Zhang Y, et al. (2007) CutDB: a proteolytic event database. Nucleic Acids Res 35: D546-D549.
31. Igarashi Y, Heureux E, Doctor KS, Talwar P, Gramatikova S, et al. (2009) PMAP: databases for analyzing proteolytic events and pathways. Nucleic Acids Res 37: D611-D618.
32. Crooks GE, Hon G, Chandonia JM, Brenner SE, (2004) WebLogo: A Sequence Logo Generator. Genome Res 14: 1188-1190.
33. McCaldon P, Argos P, (1988) Oligopeptide Biases in Protein Sequences and Their Use in Predicting Protein Coding Regions in Nucleotide-Sequences. Proteins 2: 99-122.
34. Colaert N, Helsens K, Martens L, Vandekerckhove J, Gevaert K, (2009) Improved visualization of protein consensus sequences by iceLogo. Nat Methods 6: 786-787.
35. Jones E, Oliphant T, Peterson P, et al. (2001) SciPy: Open Source Scientific Tools for Python. http://www.scipy.org.
36. Rice P, Longden I, Bleasby A, (2000) EMBOSS: The European Molecular Biology Open Software Suite. Trends Genet 6: 276-277.
37. Fitch WM, Margoliash E, (1967) Construction of phylogenetic trees. Science 3760: 279-284.
38. Letunic I, Bork P, (2011) Interactive Tree of Life v2: online annotation and display of phylogenetic trees made easy. Nucleic Acids Res 39 (Suppl 2) (): W475-W478.
39. Ekins S, Mestres J, Testa B, (2007) In silico pharmacology for drug discovery: applications to targets and beyond. Br J Pharmacol 152: 21-37.
40. Rholam M, Fahy C, (2009) Processing of peptide and hormone precursors at the dibasic cleavage sites. Cell Mol Life Sci 66: 2075-2091.
41. Lakhani SA, Masud A, Kuida K, Porter GA Jr, Booth CJ, et al. (2006) Caspases 3 and 7: Key Mediators of Mitochondrial Events of Apoptosis. Science 311: 847-851.
42. Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, et al. (1997) A Combinatorial Approach Defines Specificities of Members of the Caspase Family and Granzyme B. J Biol Chem 272: 17907-17911.
43. Walsh JG, Cullen SP, Sheridan C, Luethi A, Gerner C, et al. (2008) Executioner caspase-3 and caspase-7 are functionally distinct proteases. Proc Natl Acad Sci U S A 105: 12815-12819.
44. Ng NM, Pierce JD, Webb GI, Ratnikov BI, Wijeyewickrema LC, et al. (2011) Discovery of Amino Acid Motifs for Thrombin Cleavage and Validation Using a Model Substrate. Biochemistry 50: 10499-10507.
45. Morrison CJ, Butler GS, Rodriguez D, Overall CM, (2009) Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr Opin Cell Biol 21: 1-9.
46. Stegemann C, Didangelos A, Barallobre-Barreiro J, Langley SR, Mandal K, et al. (2013) Proteomic identification of matrix metalloproteinase substrates in the human vasculature. Circ Cardiovasc Genet 6: 106-117.
47. Checler F, Vincent JP, Kitabgi P, (1986) Purification and Characterization of a Novel Neurotensin-degrading Peptidase from Rat Brain Synaptic Membranes. J Biol Chem 261: 11274-11281.
48. Cunha FM, Berti DA, Ferreira ZS, Klitzke CF, Markus RP, et al. (2008) Intracellular Peptides as Natural Regulators of Cell Signaling. J Biol Chem 283: 24448-24459.
49. Oliveira V, Campos M, Hemerly JP, Ferro ES, Camargo ACM, et al. (2001) Selective Neurotensin-Derived Internally Quenched Fluorogenic Substrates for Neurolysin (EC 3.4.24.16): Comparison with Thimet Oligopeptidase (EC 3.4.24.15) and Neprilysin (EC 3.4.24.11). Anal Biochem 292: 257-265.
50. Husson SJ, Clynen E, Baggerman G, Janssen T, Schofs L, (2006) Defective processing of neuropeptide precursors in Caenorhabditis elegans lacking proprotein convertase 2 (KPC-2/EGL-3): mutant analysis by mass spectrometry. J Neurochem 98: 1999-2012.
51. Butler GS, Overall CM, (2009) Updated Biological Roles for Matrix Metalloproteinases and New "Intracellular" Substrates Revealed by Degradomics. Biochemistry 48: 10830-10845.
52. Pirard B, (2007) Insight into the structural determinants for selective inhibition of matrix metalloproteinases. Drug Discov Today 12: 640-646.
53. Deng SJ, Bickett DM, Mitchell JL, Lambert MH, Blackburn RK, (2000) Substrate Specificity of Human Collagenase 3 Assessed Using a Phage-displayed Peptide Library. J Biol Chem 275: 31422-31427.
54. Syntichaki P, Xu K, Driscoli M, Tavernarakis N, (2002) Specific aspartyl and calpain proteases are required for neurodegeneration in C. elegans. Nature 419: 939-944.
55. Williamson AL, Lecchi P, Turk BE, Choe Y, Hotez PJ, et al. (2004) A Multi-enzyme Cascade of Hemoglobin Proteolysis in the Intestine of Blood-feeding Hookworms. J Biol Chem 279: 35950-35957.
56. Krem MW, Di Cera E, (2001) Molecular markers of serine protease evolution. EMBO J 20: 3036-3045.
57. Rose T, Di Cera E, (2002) Substrate Recognition Drives the Evolution of Serine Proteases. J Biol Chem 277: 19243-19246.
58. Yousef GM, Kopolovic AD, Elliott MB, Diamandis EP, (2003) Genomic overview of serine proteases. Biochem Biophys Res Commun 305: 28-36.
59. Debela M, Beaufort N, Magdolen V, Schechter NM, Craik CS, et al. (2008) Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7. Biol Chem 389: 623-632.
60. Glinca S, Klebe G, (2013) Cavities Tell More than Sequences: Exploring Functional Relationships of Proteases via Binding Pockets. J Chem Inf Model 53: 2082-2092.
61. Rotonda J, Nicholson DW, Fazil KM, Gallant M, Gareau Y, et al. (1996) The three-dimensional structure of apopain/CPP32, a key mediator of apoptosis. Nat Struct Biol 3: 619-625.
62. Rotonda J, Garcia-Calvo M, Bull HG, Geissler WM, McKeever BM, et al. (2001) The three-dimensional structure of human granzyme B compared to caspase-3, key mediators of cell death with cleavage specificity for aspartic acid in P1. Chem Biol 8: 357-368.
63. Wang B, Malik R, Nigg EA, Koerner R, (2008) Evaluation of the Low-Specificity Protease Elastase for Large-Scale Phophoproteome Analysis. Anal Chem 80: 9526-9533.
64. Timmer JC, Zhu W, Pop C, Regan T, Snipas SJ, et al. (2009) Structural and kinetic determinants of protease substrates. Nat Struct Mol Biol 16: 1101-1108.
65. Buch I, Giorgino T, De Fabritiis G, (2011) Complete reconstruction of an enzyme-inhibitor binding process by molecular dynamics simulations. Proc Natl Acad Sci U S A 108: 10184-10189.
66. Deutscher MP, (1990) Maintaining protein stability. Methods Enzymol 182: 83-89.
67. White PW, Llinas-Brunet M, Amad M, Bethell RC, Bolger G, et al. (2010) Preclinical Characterization of BI 201335, a C-terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease. Antimicrob Agents Chemother 54: 4611-4618.
68. Neurath H, (1984) Evolution of Proteolytic Enzymes. Science 224: 350-357.
69. Kwan JC, Eksioglu EA, Liu C, Paul VJ, Luesch H, (2009) Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem 52: 5732-5747.
70. Nakai R, Salisbury CM, Rosen H, Cravatt BF, (2009) Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem 17: 1101-1108.
71. Collet BYM, Nagashima T, Yu MS, Pohl NLB, (2009) Fluorous-based Peptide Microarrays for Protease Screening. J Fluor Chem 130: 1042-1048.
72. Skolnick J, Gao M, (2013) Interplay of physics and evolution in the likely origin of protein biochemical function. Proc Natl Acad Sci U S A 110: 9344-9349.
73. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, et al. (2007) Relating protein pharmacology by ligand chemistry. Nat Biotechnol 25: 197-206.
74. Hert J, Keiser MJ, Irwin JJ, Oprea TI, Shoichet BK, (2008) Quantifying the Relationship among Drug Classes. J Chem Inf Model 48: 755-765.
75. Lounkine E, Keiser MJ, Whitebread S, Mikhailov D, Hamon J, et al. (2012) Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets. Nature 486: 361-367.
76. Yera EA, Cleves AE, Jain AN, (2011) Chemical Structural Novelty: On-Targets and Off-Targets. J Med Chem 54: 6771-6785.
77. Durrant JD, Amaro RE, Xie L, Urbaniak MD, Ferguson MAJ, et al. (2010) A Multidimensional Strategy to Detect Polypharmacological Targets in the Absence of Structural and Sequence Homology. PLOS Comput Biol 6: e1000648.
78. Liu X, Ouyang S, Yu B, Liu Y, Huang K, et al. (2010) PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Res 38: W609-W614.
79. Milletti F, Vulpetti A, (2010) Predicting Polypharmacology by Binding Site Similarity: From Kinases to the Protein Universe. J Chem Inf Model 50: 1418-1431.
80. Vulpetti A, Kalliokoski T, Millerri F, (2012) Chemogenomics in drug discovery: computational methods based on the comparison of binding sites. Future Med Chem 4: 1971-1979.
81. Gregori-Puigjane E, Setola V, Hert J, Crews BA, Irwin JJ, et al. (2012) Identifying mechanism-of-action targets for drugs and probes. Proc Natl Acad Sci U S A 109: 11178-11183.
82. Nobeli I, Favia AD, Thornton JM, (2009) Protein promiscuity and its implications for biotechnology. Nat Biotechnol 27: 157-167.
83. Gold ND, Deville K, Jackson RM, (2007) New opportunities for protease ligand-binding site comparisons using SitesBase. Biochem Soc Trans 35: 561-565.
84. Overington JP, Al-Lazikani B, Hopkins AL, (2006) How many drug targets are there? Nat Rev Drug Discov 5: 993-996.
85. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M, (2007) Drug-target network. Nat Biotechnol 25: 1119-1126.
86. Lu JJ, Pan W, Hu YJ, Wang YT, (2012) Multi-Target Drugs: The Trend of Drug Research and Development. PLOS One 7: e40262.